Enanta Pharmaceuticals Inc. Stock
Enanta Pharmaceuticals Inc. dominated the market today, gaining €1.20 (9.450%).
With 5 Buy predictions and 4 Sell predictions the community is currently undecided on Enanta Pharmaceuticals Inc..
As a result the target price of 26 € shows a very positive potential of 87.05% compared to the current price of 13.9 € for Enanta Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Enanta Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Enanta Pharmaceuticals Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Enanta Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc. | 9.450% | 21.930% | -7.333% | -57.099% | 57.955% | -67.371% | -81.918% |
| Ardelyx Inc. | 3.690% | 34.723% | 16.633% | 93.717% | 39.758% | 44.250% | - |
| Evolus Inc | 4.240% | 17.143% | 2.500% | 61.842% | 35.912% | 68.493% | - |
| Salarius Pharmaceuticals Inc. | -1.300% | 6.573% | 5.581% | -68.472% | -18.198% | -98.220% | -99.993% |
Comments
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at JMP Securities from $42.00 to $23.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ENTA provided by MarketBeat